Edition:
United Kingdom

Glaukos Corp (GKOS.N)

GKOS.N on New York Stock Exchange

29.45USD
2:33pm GMT
Change (% chg)

$-0.17 (-0.57%)
Prev Close
$29.62
Open
$29.58
Day's High
$29.58
Day's Low
$29.39
Volume
5,271
Avg. Vol
153,197
52-wk High
$52.41
52-wk Low
$23.10

Chart for

About

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision... (more)

Overall

Beta: --
Market Cap(Mil.): $1,156.64
Shares Outstanding(Mil.): 34.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.28 16.58
EPS (TTM): -- -- --
ROI: -- 13.90 10.60
ROE: -- 16.71 14.19

BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort

* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT

10 Jan 2018

BRIEF-Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System

* GLAUKOS SUBMITS IDE APPLICATION TO FDA TO STUDY ISTENT INFINITE™ TRABECULAR MICRO-BYPASS SYSTEM

03 Jan 2018

BRIEF-Glaukos Corp posts Q3 earnings per share $0.04

* Glaukos Corporation announces third quarter 2017 financial results

07 Nov 2017

BRIEF-James Flynn reports a 7.34 pct passive stake in Glaukos

* James E. Flynn reports a 7.34 Pct passive stake in Glaukos Corp as of Sept 14 - SEC filing Source text: [http://bit.ly/2xBLsij] Further company coverage:

25 Sep 2017

BRIEF-Glaukos Corporation Q2 loss per share $0.10

* Glaukos Corporation announces second quarter 2017 financial results

02 Aug 2017

Earnings vs. Estimates